SP-420
- Generic Name
- SP-420
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21NO6S
- CAS Number
- 911714-45-9
- Unique Ingredient Identifier
- WBX54NZ436
- Background
SP-420 is under investigation in clinical trial NCT03801889 (SP-420 in Subjects With Transfusion-dependent Beta-thalassemia or Other Rare Anemias).
- Associated Conditions
- -
- Associated Therapies
- -
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Pharmacosmos A/S
- Target Recruit Count
- 90
- Registration Number
- NCT05693909
- Locations
- 🇩🇰
Pharmacosmos Investigational Site, Copenhagen, Denmark
Safety of SP-420 in the Treatment of Transfusional Iron Overload
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2023-12-12
- Target Recruit Count
- 28
- Registration Number
- NCT04741542
- Locations
- 🇺🇸
Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States
SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Abfero Pharmaceuticals, Inc
- Registration Number
- NCT03801889
- Locations
- 🇨🇦
University of Toronto- University Health Network, Toronto, Canada
🇱🇧American University of Beirut Medical Center, Beirut, Lebanon
🇹🇷Ege University Hospital, İzmir, Turkey
Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2015-09-29
- Lead Sponsor
- Sideris Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02274233
- Locations
- 🇹🇷
Sideris Investigative Site, Izmir, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath